Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review

Introduction: Neuroendocrine tumors (NETs) comprise <1% of all bladder tumors,characterized by poor prognosis. These tumors may be either pure or impure, intermixed with urothelial carcinoma. There is currently no therapeutic consensus. We report the case of primary impure neuroendocrine carcinoma (NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: urinary bladder, mixed tumor, urothelial carcinoma, neuroendocrine carcinoma, chemotherapy, radiotherapy,

#2891 Bone Metastases and Skeletal Related Events in Patients with Neuroendocrine Neoplasms (NEN): The Role of Zoledronic Acid

Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,

Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,

#2835 Primary Hepatic Neuroendocrine Carcinoma: Case Report and Literature Review

Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: primary hepatic neuroendocrine carcinoma, liver biopsy, immunohistochemical staining, Somatostatin analogue,

#2832 Lymph Node Merkel Cell Carcinoma without Primary: Long Term Survival

Introduction: Merkel cell carcinoma (MCC) is a rare aggressive cutaneous neuroendocrine carcinoma with a high rate of metastasis. Approximately 5% of MCC are found in the lymph nodes (LNs) without a primary tumor on the skin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: merkel cell carcinoma, lymph node metastasis, unknown primary, surgery, radiotherapy,